Intraocular Melanoma Treatment Market: New Business Opportunities and Investment Research Report

Intraocular
(uveal) melanoma is a rare eye cancer, characterized with
blurred vision or a dark spot on the iris. Various treatment options
are available for intraocular melanoma, such as eye examinations.
According to the National Cancer Institute (NCI), the standard
treatments include surgery, radiation therapy, photocoagulation, and
thermotherapy. Along with these standard treatments, some other
treatments are also being tested in clinical trials. For instance,
Nivolumab: an immunotherapy drugs shown to help people suffering from
uveal melanoma by increasing patient’s overall immunity, are
presently in Phase II clinical study. Additionally, other similar
drugs being studied for uveal melanoma include combination of
Ipilimumab and Nivolumab, and Selumetinib. Selumetinib is a targeted
drug known to slow down the growth of eye melanoma, while nivolumab
in combination with lpilimumab are being studied to control uveal
melanoma are present in Phase II clinical study.
According to American
Society of Clinical Oncology (ASCO), individuals belonging to
Caucasian race, people with light eye color and fair skin, or any
individual and any of their family member having history of suffering
from dysplastic nevus syndrome, seem to have a higher risk of
developing intraocular melanoma. Moreover, over-exposure to sunlight,
a known risk factor for melanoma of the skin, is also a risk factor
for intraocular melanoma. These factors in turn, are expected to
boost growth of the intraocular melanoma treatment market in the near
future.
Request Sample Copy of
Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1854
Intraocular Melanoma
Treatment Market – Regional Analysis
Geographically, the
global intraocular melanoma treatment market is segmented into North
America, Latin America, Europe, Middle East, Asia Pacific, and
Africa. North America accounted for the major market share in 2017
and is expected to show lucrative growth opportunities in the near
future, owing to increasing engagement of various government and
private organizations in developing effective treatment options and
rising incidence of intraocular melanoma in the region. For instance,
according to the National Cancer Institute (NCI) data in 2016, the
mean age-adjusted incidence of uveal melanoma in the U.S. is around
4.3-8.4 new cases per million people per year.
Several research
organizations, in the regions are engaged in raising funding for
research to develop intraocular melanoma treatment options. For
instance, Melanoma Research Foundation (MRF), a Washington-based
organization committed to develop effective treatment in various
types of melanoma, raised around US$ 1.2 million for ocular melanoma
and its treatment, since 2012. Furthermore, in April 2018, the Ocular
Melanoma Foundation (OMF), in collaboration with the American
Association for Cancer Research (AACR), offered research funding of
US$ 150,000 to researchers at the Casey Eye Institute, to study
circulating hybrid tumor cells as a prognostic biomarker for ocular
melanoma.
Intraocular Melanoma Treatment Market
Competitive Landscape
Some of the key
players operating in the intraocular melanoma market are Astra Zeneca
plc, Eli Lilly & Co., Pfizer, Inc. Novartis AG, and Spectrum
Pharmaceuticals, Inc.
Request For
Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1854
Intraocular Melanoma Treatment Market Taxonomy
By Treatment
• Targeted
Therapy
◦ Rituximab
(Rituxan)
◦
Ibritumomab (Zevalin)
◦ Imatinib
(Gleevec)
◦ Sorafenib
(Nexavar)
• Other
Therapies
By End User:
• Hospitals
• Specialty
Clinics
• Ambulatory
Surgical Centers
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
About Coherent Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment